Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2004-01-06
2010-02-02
Tsang, Cecilia (Department: 1654)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S015800
Reexamination Certificate
active
07655622
ABSTRACT:
Methods for regulating body weight and/or regulating weight gain are provided herein. The methods are useful, for instance, for treating or preventing obesity. Specifically, methods of administering varying levels of various alpha melanocyte stimulating hormone (α-MSH) analog compounds to an animal are provided for reducing body weight and/or reducing the rate of body weight gain.
REFERENCES:
patent: 4485039 (1984-11-01), Hruby et al.
patent: 4649191 (1987-03-01), Hruby
patent: 4874744 (1989-10-01), Norlund et al.
patent: 4918055 (1990-04-01), Hruby et al.
patent: 5420109 (1995-05-01), Suto et al.
patent: 5532347 (1996-07-01), Cone et al.
patent: 5580859 (1996-12-01), Felgner et al.
patent: 5589466 (1996-12-01), Felgner et al.
patent: 5593972 (1997-01-01), Weiner et al.
patent: 5641662 (1997-06-01), Debs et al.
patent: 5674839 (1997-10-01), Hruby et al.
patent: 5676954 (1997-10-01), Brigham
patent: 5683981 (1997-11-01), Hadley et al.
patent: 5691309 (1997-11-01), Basinski et al.
patent: 5703220 (1997-12-01), Yamada et al.
patent: 5710265 (1998-01-01), Yamada et al.
patent: 5714576 (1998-02-01), Hruby et al.
patent: 5726156 (1998-03-01), Girten et al.
patent: 5731408 (1998-03-01), Hadley et al.
patent: 5756461 (1998-05-01), Stephens
patent: 5760001 (1998-06-01), Girten et al.
patent: 5766877 (1998-06-01), Stark et al.
patent: 5773416 (1998-06-01), Chehab
patent: 5780258 (1998-07-01), de la Brousse et al.
patent: 5786332 (1998-07-01), Girten et al.
patent: 5830450 (1998-11-01), Lallone
patent: 5830994 (1998-11-01), D'Hinterland et al.
patent: 5831017 (1998-11-01), Hoffmann
patent: 5843652 (1998-12-01), Woychik
patent: 5846734 (1998-12-01), Serrero
patent: 5849708 (1998-12-01), Maratos-Flier
patent: 5851995 (1998-12-01), Basinski et al.
patent: 5866547 (1999-02-01), Flier et al.
patent: 5869452 (1999-02-01), Ng et al.
patent: 5908609 (1999-06-01), Lee et al.
patent: 5932779 (1999-08-01), Lee et al.
patent: 6127381 (2000-10-01), Basu et al.
patent: 6245738 (2001-06-01), Suto et al.
patent: 6278038 (2001-08-01), Cone et al.
patent: 6344481 (2002-02-01), Cornelius et al.
patent: 6350430 (2002-02-01), Dooley et al.
patent: 6376509 (2002-04-01), Bakshi et al.
patent: 6603058 (2003-08-01), Brennan et al.
patent: 6608082 (2003-08-01), Basu et al.
patent: 6689938 (2004-02-01), Brennan et al.
patent: 6716810 (2004-04-01), Brennan et al.
patent: 2006/0063708 (2006-03-01), Brennan et al.
patent: 0 292 291 (1988-05-01), None
patent: WO95/13086 (1995-05-01), None
patent: WO96/27386 (1996-09-01), None
patent: WO 97/47316 (1997-12-01), None
patent: WO 98/10068 (1998-03-01), None
patent: WO 99/21571 (1999-05-01), None
patent: WO 99/55679 (1999-11-01), None
patent: WO 00/35952 (2000-06-01), None
Sawyer et al. [half-Cys4,half-Cys10]-a-Melanocyte-stimulating hormone: A cyclic a-melanotropin exhibiting superagonist biological activity. Proc Natl Acad Sci USA 1982, vol. 79, pp. 1751-1755.
Considine et al. Serum Immunoreactive-Leptin Concentrations in Normal-Weight and Obese Humans. The New England Journal of Medicine. Feb. 1, 1996. pp. 292-295.
Fisher et al. Melanocortin-4 receptor: A novel signalling pathway involved in body weight regulation. International Journal of Obesity. 1999. Vo.. 23, Suppl 1, pp. 54-58.
California Peptide Research, MW of Alpha MSH Ac-Nle4 c[Asp5-DPhe7 Lys10] 4-10 amide. Accessed online on Jun. 23, 2007 at http://www.californiapeptide.com/catalog.php?page=2&f=&search=&srchfld=&PHPSESSID=191fcdd62dc39e55a377b9906b4c79ae. 3rdcompound in p. 1 (1 page).
Blüher, et al.; “Responsiveness to Peripherally Administered Melanocortins in Lean and Obese Mice;” Diabetes, vol. 53, Jan. 2004, pp. 82-90.
Fan, Wei et al.; Role of melanocortinergic neurons in feeding and theagoutiobesity syndrome; Nature; vol. 385; pp. 165-168; Jan. 9, 1997.
Friedman, Jeffery M.; The alphabet of weight control; Nature; vol. 385; pp. 119-120; Jan. 9, 1997.
Huszar, Dennis et al.; Targeted Disruption of the Melanocortin-4 Receptor Results in Obesity in Mice; Cell; vol. 88; pp. 131-141; Jan. 10, 1997.
Poggioli, R. et al.; “ACTH- (1-24) and alpha-MSH antagonize feeding behavior stimulated by kappa opiate antagonists;” Peptides, Elsevier, Amsterdam, US, vol. 7, No. 5; 1986; pp. 843-848; XP009018115.
Fan, W. et al.; “Role of Melanocortinergic Neurons in Feeding and the Agouti Obesity Syndrome;” Nature, Macmillan Journals Ltd., London, GB; vol. 385; Jan. 9, 1997; pp. 165-168; XP002072475.
Huszar, D. et al.; “Targeted Disruption of the Melanocortin-4 Receptor Results in Obesity in Mice;” Cell, Cell Press, Cambridge,, NA, US; vol. 88, No. 1; Jan. 10, 1997; pp. 131-141; XP000877328.
“A Frameshift Mutation in Human MC4R is Associated with a Dominant Form of Obesity;” Nature Genetics, New York, NY, US; vol. 20, No. 2; Oct. 1998; pp. 113-114; XP000866527.
“A Frameshift Mutation in MC4R Associated with Dominantly Inherited Human Obesity;” Nature Genetics, New York, NY, US; vol. 20, No. 2; Oct. 1998; pp. 111-112; XP000866528.
Chagnon, Yvon C. et al.; “Linkage and association studies between the melanocortin receptors 4 and 5 genes and obesity-related phenotypes in the Quebec Family Study;” Molecular Medicine, New York; vol. 3, No. 10; Oct. 1997; pp. 663-673; XP009046979.
Jackson, R.S. et al.; “Proopiomelanocortin products and human early-onset obesity;” The Journal of Clinical Endocrinology and Metabolism; Feb. 1999; pp. 819-820; XP002326389.
Mizuno, T.M. et al.; “Hypothalamic Pro-Opiomelanocortin MRNA is Reduced by Fasting in OB/OB and DB/DB Mice, but is Stimulated by Leptin;” Diabetes, New York, NY, US; vol. 47., No. 2; Feb. 1998; pp. 294-297; XP001063909.
Cheung, C.C. et al.; “Proopiomelanocortin Neurons are Direct Targets for Leptin in the Hypothalamus;” Endocrinology; Baltimore, MD, US; vol. 138, No. 10; 1997; pp. 4489-4492; XP009027762.
Boston, Bruce A. et al.; “Characterization of melanocortin receptor subtype expression in murine adipose tissues and in the 3T3-L1 cell line;” Endocrinology; vol. 137, No. 5; 1996; pp. 2043-2050; XP002326390.
Bertagna, Xavier; “Proopiomelanocortin-derived peptides;” Endocrinology and Metabolism Clinics of North America; vol. 23, No. 3; 1994; pp. 467-485; XP009046900.
Abou-Mohamed, G.; Papapetropoulos, A.; Ulrich, D.; Catravas, J.D.; Tuttle, R.R.; and Caldwell, R.W., “HP-228, A Novel Synthetic Peptide, Inhibits the Induction of Nitric Oxide Synthase In Vivo But Not In Vitro,”The Journal of Pharmacology and Experimental Therapeutics, vol. 275, No. 2, 584-591 (1995).
Corcos, I; Thompson, E.E.; Omholt, P. MD; McPherson, Lee S.; McDowell, R.; Houghten, R.; and Girten, B., “HP 228 is a potential agonist of melanocortin receptor 4, and significantly attenuates obesity and diabetes in Zucker fatty rats,”Society for Neuroscience,vol. 23, Abstract 267.9 (1997).
Compound May Utilize Newly Discovered Signaling Pathway URL: http://www.pslgroup.com/dg/124DA.htm; Doctor''s Guide; Jan. 17, 1997.
Trega Biosciences Inc; Form: 10-K405 Filing; Mar. 31, 1999.
Rubinstein et al.;Nucleic Acids Research; 21(11):2613-2617; 1993.
Mullins et al.; “Perspective Series: Molecular Medicine in Genetically Engineered Animals—Transgenesis in the Rat and Larger Mammals;” Transgenesis in Nonmarine Species; J. Clin. Invest., vol. 97, No. 7, pp. 1557-1560; Apr. 1996.
Moreadith et al.; “Gene Targeting in Embryonic Stem Cells: The New Physiology and Metabolism;” J. Mol. Med.; 75:[pp. 208-216]; 1997.
Krude et al.; Nature Genetics; 19:155-157; 1998.
Yaswen et al.; “Obesity in the Mouse Model of Pro-Opiomelanocortin Deficiency Responds to Peripheral Melanocortin;” Nature Medicine; vol. 5, No. 9, pp. 1066-1070; Sep. 1999.
Pera et al.; “Human Embryonic Stem Cells;” J. Cell Science 113; pp. 5-10; 2000.
Brennan Miles B.
Hochgeschwender Ute
Brinks Hofer Gilson & Lione
Cordero Garcia Marcela M
Eleanor Roosevelt Institute
Oklahoma Medical Research Foundation
Tsang Cecilia
LandOfFree
Composition and method for regulation of body weight and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Composition and method for regulation of body weight and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Composition and method for regulation of body weight and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4189019